Story perspectives

Novo Nordisk Stock Plummets 12% Amid Sales Forecast Drop

2/3/2026

Summary

Story summary

Novo Nordisk's stock fell over 12% on February 3, 2026, after projecting a 5%–13% decline in sales and profit.
The drop follows competition from Eli Lilly and U.S. pricing pressures.
Novo Nordisk expects loss of exclusivity for Wegovy and Ozempic in several countries.
CEO Mike Doustdar expressed optimism about the early Wegovy pill uptake.
The company announced a DKK 15 billion share buyback.

History

Historical Context

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 established Medicare Part D, allowing private insurers to provide drug coverage without enabling Medicare to negotiate prices. This led to rising drug costs and market dynamics that affected companies like Eli Lilly and Novo Nordisk. By 2026, Novo Nordisk faced a 12% stock decline due to competitive pressures and loss of product exclusivity, highlighting ongoing industry challenges.

1 of 2

Story summary

Novo Nordisk's stock fell over 12% on February 3, 2026, after projecting a 5%–13% decline in sales and profit.
The drop follows competition from Eli Lilly and U.S. pricing pressures.
Novo Nordisk expects loss of exclusivity for Wegovy and Ozempic in several countries.
CEO Mike Doustdar expressed optimism about the early Wegovy pill uptake.
The company announced a DKK 15 billion share buyback.

1 / 2